Abstract P1-18-30: Neoadjuvant aromatase inhibitor and pertuzumab and trastuzumab (NEOADAPT) up to one year for HR+HER2+ breast cancer: Results from a prematurely closed de-escalation study
Abstract:Background. Current standard of care for HR+HER2+ breast cancer >1cm per NCCN guidelines is chemotherapy with either trastuzumab(T) or trastuzumab and pertuzumab(TP) with anti-HER2 therapy continued for 1 year and anti-hormonal therapy for 5-10 years. Patients with HR+HER2+ breast cancer benefit less from chemotherapy than those with HR-HER2+ breast cancer. Recent studies show that pCR rates with aromatase inhibitor and dual-HER2 blockade for 3-6 months duration range between 21%- 33% with the highest p… Show more
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.